Catalyst MedTech Launches Connect Program for Advanced Imaging
Catalyst MedTech has unveiled its latest initiative, the Connect program, designed to bring together innovators aiming to enhance patient care with the necessary resources to achieve this. This program stands out thanks to Catalyst's dual business model, which encompasses both Equipment Solutions and Clinical Solutions. By implementing this program, Catalyst aims to create customized routes that facilitate greater access to diagnostic imaging and treatment options. Connect is dedicated to ensuring innovations reach the patients who need them most.
Partnership with Algernon Pharmaceuticals
As part of the initiative's rollout, Catalyst MedTech has entered into its first partnership with Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF). Algernon is a publicly traded healthcare company committed to expanding access to Optimized Brain PET imaging. This collaboration will enable Algernon to establish the first dedicated network of neuroimaging clinics aimed at the early detection of Alzheimer’s disease. Catalyst MedTech will support this mission by providing a customized mix of equipment, services, and support, featuring the Optimized Brain PET solution, which integrates CareMiBrain™ and the NeuroQ® advanced quantitative workstation.
Importance of the Connect Program
Martin B Shirley, CEO & President of Catalyst MedTech, expressed the vision behind Connect. He stated, "The vision of Connect is to help finish the story for our partners. Many companies aspire to make significant impacts in areas like neurology and cardiology. Catalyst serves as the connector that transforms these ambitions into reality by supplying the access, expertise, and solutions essential for translating vision into actionable results, reaching patients for their benefit." This powerful commitment to bridging gaps in innovation and patient access is vital in the fast-evolving field of healthcare.
Advancements in Brain Imaging Technology
The rising number of individuals at risk for Alzheimer’s and similar conditions emphasizes the need for dedicated Brain PET technology for timely and accurate diagnoses. Catalyst MedTech’s CareMiBrain™ system, distributed exclusively in the U.S., sets a new standard in neurologic imaging. With ultra-high resolution imaging capabilities combined with an advanced quantitative neurologic workstation, this system enhances diagnostic precision while enabling scalability suitable for various healthcare settings, including neurology practices, imaging centers, and hospitals.
Feedback from Partners
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, shared his excitement regarding the collaboration, stating, "We are very excited to be working with Catalyst MedTech to accelerate access to Brain PET in the U.S. Catalyst’s capacity to bridge innovation, access, and patient care aligns perfectly with our goal of developing an advanced neuroimaging clinic network. Together, we aim to significantly improve the diagnosis and treatment of Alzheimer’s and other neurodegenerative conditions."
The Commitment of Catalyst MedTech
Catalyst MedTech continues to be a leader in advanced imaging solutions, establishing pathways for adopting new technologies that ultimately result in improved patient care. This commitment ensures that breakthroughs in imaging lead to beneficial outcomes, offering patients earlier answers and better diagnostic capabilities.
About Catalyst MedTech
Catalyst MedTech operates nationwide, providing solutions in nuclear medicine, molecular imaging, and CT technology. Their objective is clear and impactful: to enhance value and access through advanced diagnostic imaging and related therapies, ultimately ensuring that patients receive the care they deserve.
Clinical Expertise and Equipment Support
With teams trained in original equipment manufacturing (OEM) standards, Catalyst MedTech brings clinical expertise and a versatile equipment portfolio to healthcare providers in cardiology, neurology, and beyond. As a leading independent ISO-certified service provider in nuclear medicine and molecular imaging in the U.S., Catalyst MedTech aids healthcare organizations in delivering swift, effective diagnostics and fostering better health outcomes.
Frequently Asked Questions
What is the Connect program by Catalyst MedTech?
The Connect program is an initiative aimed at facilitating collaboration between innovators to enhance patient care with increased access to advanced imaging and treatment solutions.
Who is the first partner of the Connect program?
Catalyst MedTech's first Connect partnership is with Algernon Pharmaceuticals, focusing on the establishment of neuroimaging clinics for early Alzheimer’s detection.
What technology does the CareMiBrain™ system offer?
The CareMiBrain™ system offers ultra-high resolution imaging coupled with an advanced quantitative neurologic workstation, providing precise diagnostics and scalability.
What impact does the partnership aim to achieve?
The partnership plans to significantly improve how Alzheimer's and other neurodegenerative diseases are diagnosed and treated through enhanced neuroimaging access.
How does Catalyst MedTech support healthcare providers?
Catalyst MedTech supports providers with OEM-trained service teams, clinical expertise, and a robust equipment portfolio, enabling better diagnostic capabilities and patient outcomes.
